US 10,441,653 B2 · Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant

Abstract

The present invention relates to a nucleic acid of the general formula (I): GIXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.

A method of stimulating an immune response to a disease antigen, comprising administering to a patient in need thereof a composition comprising:

(a) the disease antigen or nucleic acid encoding a disease antigen;
and
(b) a pharmaceutically effective amount of an adjuvant nucleic acid, wherein the adjuvant nucleic acid comprises at least one adjuvant nucleic acid sequence selected from the following sequences:
(SEQ ID NO:
1)
GGUUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
2)
GGGGGUUUUUUUUUUGGGGG;
(SEQ ID NO:
3)
GGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGG;
(SEQ ID NO:
4)
GUGUGUGUGUGUUUUUUUUUUUUUUUUGUGUGUGUGUGU;
(SEQ ID NO:
5)
GGUUGGUUGGUUUUUUUUUUUUUUUUUGGUUGGUUGGUU;
(SEQ ID NO:
10)
GGGGGGUUUUUUUUGGGGGG;
(SEQ ID NO:
11)
GGGGGGUUUUUUUUUGGGGG;
(SEQ ID NO:
12)
GGGGGGUUUUUUUUUUGGGG;
(SEQ ID NO:
13)
GGGGGUUUUUUUUUUUGGGG;
(SEQ ID NO:
14)
GGGGGUUUUUUUUUUUUGGG;
(SEQ ID NO:
15)
GGGGUUUUUUUUUUUUUGGG;
(SEQ ID NO:
16)
GGGGUUUUUUUUUUUUUUGG;
(SEQ ID NO:
17)
GGUUUUUUUUUUUUUUUUGG;
(SEQ ID NO:
18)
GUUUUUUUUUUUUUUUUUUG;
(SEQ ID NO:
23)
GGGGGGGUUUUUUUUGGGGGGG;
(SEQ ID NO:
24)
GGGGGGGUUUUUUUUUGGGGGG;
(SEQ ID NO:
25)
GGGGGGGUUUUUUUUUUGGGGG;
(SEQ ID NO:
26)
GGGGGGUUUUUUUUUUUGGGGG;
(SEQ ID NO:
27)
GGGGGGUUUUUUUUUUUUGGGG;
(SEQ ID NO:
28)
GGGGGUUUUUUUUUUUUUGGGG;
(SEQ ID NO:
29)
GGGGGUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
30)
GGGUUUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
31)
GGUUUUUUUUUUUUUUUUUUGG;
(SEQ ID NO:
36)
GGGGGGGGUUUUUUUUGGGGGGGG;
(SEQ ID NO:
37)
GGGGGGGGUUUUUUUUUGGGGGGG;
(SEQ ID NO:
38)
GGGGGGGGUUUUUUUUUUGGGGGG;
(SEQ ID NO:
39)
GGGGGGGUUUUUUUUUUUGGGGGG;
(SEQ ID NO:
40)
GGGGGGGUUUUUUUUUUUUGGGGG;
(SEQ ID NO:
41)
GGGGGGUUUUUUUUUUUUUGGGGG;
(SEQ ID NO:
42)
GGGGGGUUUUUUUUUUUUUUGGGG;
(SEQ ID NO:
43)
GGGGUUUUUUUUUUUUUUUUGGGG;
(SEQ ID NO:
44)
GGGUUUUUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
45)
GUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUG;
(SEQ ID NO:
46)
GGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGG;
(SEQ ID NO:
47)
GGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
48)
GGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGG;
(SEQ ID NO:
49)
GGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGG;
(SEQ ID NO:
50)
GGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGG;
(SEQ ID NO:
51)
GGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGG;
(SEQ ID NO:
52)
GGGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGGG;
(SEQ ID NO:
53)
GGGGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGGGG;
(SEQ ID NO:
59)
GGUUUUUUUUGG;
(SEQ ID NO:
60)
GGUUUUUUUUUGG;
(SEQ ID NO:
61)
GGUUUUUUUUUUGG;
(SEQ ID NO:
62)
GGUUUUUUUUUUUGG;
(SEQ ID NO:
63)
GGUUUUUUUUUUUUGG;
(SEQ ID NO:
64)
GGUUUUUUUUUUUUUGG;
(SEQ ID NO:
65)
GGUUUUUUUUUUUUUUGG;
(SEQ ID NO:
66)
GGUUUUUUUUUUUUUUUGG;
(SEQ ID NO:
72)
GGGUUUUUUUUGGG;
(SEQ ID NO:
73)
GGGUUUUUUUUUGGG;
(SEQ ID NO:
74)
GGGUUUUUUUUUUGGG;
(SEQ ID NO:
75)
GGGUUUUUUUUUUUGGG;
(SEQ ID NO:
76)
GGGUUUUUUUUUUUUGGG;
(SEQ ID NO:
77)
GGGUUUUUUUUUUUUUGGG;
(SEQ ID NO:
78)
GGGUUUUUUUUUUUUUUUGGGUUUUUUUUUUUUUUUGGGUUUUUUUUUUU
UUUUGGG;
(SEQ ID NO:
79)
GGGUUUUUUUUUUUUUUUGGGGGGUUUUUUUUUUUUUUUGGG;
and
wherein the immune response to the disease antigen or disease antigen nucleic acid is greater than if the patient was provided the disease antigen or disease antigen nucleic acid without the adjuvant nucleic acid.

174 more elements

Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant

Life of this patent

Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant

Life of this patent

Abstract

Claims33